Lipocine Inc.
For the period ended May 19, 2026. Filed May 19, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 19, 2026 · Filed May 19, 2026
Use the contents to explore the available documents and sections.
LPCN$1.57+2.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Poster Presentation
Poster Presentation
| Date: | Wednesday, May 27, 2026 |
|---|---|
| Time: | 11:45 AM – 1:30 PM ET |
| Session: | Poster Session 1, Pharmaceutical Pipeline |
| Poster number: | W98 |
“We are pleased that our Phase 3 data for LPCN 1154 was selected for an oral presentation at this year’s ASCP meeting, a leading forum for clinical psychopharmacology research,” said Mahesh V. Patel, Ph.D., President and Chief Executive Officer of Lipocine.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.